Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Dyadic International Inc. (DYAI) news

The news and the share price important stories, numbered as below

Share price since 16 October −20.5%

Stories the last two months, newest first

  1. 1 Results ·

    Dyadic reports third-quarter revenue of $449,101 and a $1.36 million loss

    Dyadic reported Q3 revenue of $449,000, down 61% year over year, while nine-month revenue was essentially flat at $2.5 million. It recorded its first direct sales of recombinant proteins, but recurring sales remained modest and customer adoption was slower than expected. Dyadic ended the quarter with about $6 million in cash and disclosed substantial doubt about its ability to continue as a going concern over the next 12 months.

    Reported by 3: GlobeNewswire · GuruFocus.com · The Motley Fool

  2. Commentary ·

    Dyadic’s partnerships and funding needs shape its commercialization strategy

    Dyadic is shifting toward larger strategic partnerships because direct sales face lengthy customer qualification timelines and the company lacks capital to scale manufacturing independently. Management says partners with infrastructure and distribution can commercialize its platforms more efficiently. A Gates-funded program reported C1 production yields of 12.1 g/L for an RSV antibody and 13.2 g/L for a malaria antibody, while further testing and development remain necessary.

    Reported by The Motley Fool

  3. Product ·

    Dyadic’s RSV and malaria antibodies enter animal studies

    Gates Medical Research Institute began mouse pharmacokinetic studies comparing Dyadic’s C1-produced RSV antibody RSM01 and malaria antibody MAM01 with CHO-produced versions. The studies followed independent binding tests by Duke University and RSV neutralization testing by IQVIA. Dyadic reported fermentation yields of 12.1 g/L for RSM01 and 13.2 g/L for MAM01; both antibodies remain in preclinical evaluation.

    Reported by GlobeNewswire

  4. Deal ·

    Dyadic, BRIG BIO and Strive target commercial alpha-lactalbumin supply

    Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition are collaborating to develop and potentially commercialize precision-fermented bovine alpha-lactalbumin for Strive’s FREEMILK platform and other nutrition products. Dyadic and BRIG BIO will optimize production, while Strive evaluates samples. Subject to development, scale-up, regulatory and quality requirements and definitive agreements, the companies target initial supply above 10 metric tonnes and longer-term annual production above 200 tonnes.

    Reported by GlobeNewswire

More headlines